Compare TTGT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTGT | OABI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.4M | 391.4M |
| IPO Year | 2024 | N/A |
| Metric | TTGT | OABI |
|---|---|---|
| Price | $3.59 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $10.75 | $4.50 |
| AVG Volume (30 Days) | 362.4K | ★ 538.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | $52.42 |
| Revenue Next Year | $2.75 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.41 | $1.32 |
| 52 Week High | $9.00 | $2.79 |
| Indicator | TTGT | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 34.54 | 53.16 |
| Support Level | $3.52 | $1.75 |
| Resistance Level | $4.75 | $2.79 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 7.58 | 43.92 |
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.